BXTAccelyon Blog

A study published in September 2017, titled: ‘Quality of life after brachytherapy or bilateral nerve‐sparing robot‐assisted radical prostate

New guidelines around PSA testing promise to transform prostate cancer outcomes in Australia. The guidelines, which recommend that asymptoma

BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide and the sole distribution partner outs

BXTAccelyon is pleased to announce that its Benelux, LDR Brachytherapy conference taking place on the 27th January 2018 at the Museum Aan De

Prostate cancer is the most common form of cancer in men, and will directly or indirectly effect most of us in our lifetime.  With new resea

BXTAccelyon is dedicated to raising awareness of LDR brachytherapy (LDR-B) and the full range of treatment options available to prostate can

Jeremy Hunt has affirmed his support for an appeal to raise £2 million towards the construction of a world-class NHS Urology Centre at the R

New Zealand brachytherapy patient and prostate cancer survivor, Bruce Stewart, recently shared his story with Fairfax Media New Zealand – se

More men in Northern Ireland are surviving prostate cancer thanks to the latest advances in treatment being carried out by specialists in Be

Prostate cancer is the most common cancer in men in the UK, and arguably the most intimate too, which can cause some patients to feel embarr